Ergomed Share Chat (ERGO)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Ergomed	LSE:ERGO	London	Ordinary Share	GB00BN7ZCY67	ORD 1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	210.00p	206.00p	214.00p	210.00p	210.00p	210.00p	22,354	07:41:10

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	47.6	-4.4	-11.0	-	93.89

Ergomed Share Discussion Threads

Showing 226 to 250 of 250 messages

Chat Pages: 10 9 8 7 6 5 4 3 2 1

Date	Subject	Author	Discuss
18/4/2018 10:59	Strategic Equity Capital plc above 5%	mfhmfh	Read Full Thread Reply
13/4/2018 13:21	after this week's results, Stephen Stamp and the CEO of the fast growing Pharmacovigilance division discuss the strategic focus on that exciting opportunities in Services. 20 min interview here: https://www.equitydevelopment.co.uk/webinars/?d=%3D%3DAOwQjM&ltkn=[ID]	edmonda	Read Full Thread Reply
12/4/2018 14:40	Sodding great loss = solid results?	jamtomorrow2	Read Full Thread Reply
11/4/2018 09:22	solid results today. Outlook sounds positive with potential acquisitions to come: 'A contracted backlog of £88 million underpins Ergomed's ability to deliver its targets for 2018. Drug Safety and Medical Information services make up an increasing proportion of our overall revenues and owing to their greater predictability and exceptional growth we benefit from greater visibility than with clinical research services which, although capable of attractive margins are lumpy by nature and highly competitive. More generally during the coming period we expect to continue to deliver on our strategy of focusing on the growth and profitability of our services businesses, supplemented by acquisitions that expand the services offering or geographical coverage, or both.' All IMHO.	mfhmfh	Read Full Thread Reply
09/3/2018 14:02	PrimeVigilance@PrimeVigilance PrimeVigilance Ltd on #Google	piedro	Read Full Thread Reply
05/3/2018 07:25	Is that Trading Update supposed to be a profit warning?	piedro	Read Full Thread Reply
22/2/2018 12:00	ORYX INTERNATIONAL GROWTH FUND >4%	mfhmfh	Read Full Thread Reply
16/2/2018 15:18	solid buys coming in today	mfhmfh	Read Full Thread Reply
07/2/2018 11:41	Octopus Investments Nominees Limited above 7%	mfhmfh	Read Full Thread Reply
06/2/2018 09:16	Slater investments above 10%	mfhmfh	Read Full Thread Reply
29/1/2018 15:44	Nice little proactive article below - gets blocked !! hTTp://www.proa_t_v_investors.co.uk/companies/news/190625/ergomed-update-underlines-the-potential-of-the-company-s-primevigilance-unit-190625.html	piedro	Read Full Thread Reply
25/1/2018 16:58	Nice little proactive article below:- Ergomed’s drugs safety unit alone is worth as much as the whole business [...]	bermudashorts	Read Full Thread Reply
25/1/2018 16:47	Numis reiterates 300p target price today	mfhmfh	Read Full Thread Reply
25/1/2018 16:43	yes strong update this morning.	bermudashorts	Read Full Thread Reply
25/1/2018 14:50	- staircase, tighter spread	piedro	Read Full Thread Reply
23/1/2018 14:38	Unless they're some sort of transfer, would have expected a postitve move in share price with buys at that level.	bermudashorts	Read Full Thread Reply
23/1/2018 13:41	We should get an RNS 1,356,372 of 42,680,813 ord shares = 3.18% {x2 = 6.38%}	piedro	Read Full Thread Reply
23/1/2018 12:03	2 big buys/huge volume today.	mfhmfh	Read Full Thread Reply
17/1/2018 13:52	Anybody know when to expect a trading update ?	nchanning	Read Full Thread Reply
08/1/2018 15:39	FWIW ... Equity Development Ergomed plc 2018 – creating further value https://tinyurl.com/y9l8a45e	piedro	Read Full Thread Reply
02/1/2018 16:49	Timbo/anyone still here? Any thoughts on replacement of Dr Dan Weng as CEO? He didn't last very long!	bermudashorts	Read Full Thread Reply
12/12/2017 09:52	https://www.investegate.co.uk/ergomed-plc--ergo-/rns/co-dev-partnership-with-allergy-therapeutics/201712120700040254Z/	amchw	Read Full Thread Reply
01/11/2017 18:08	Thanks - will be interesting not to follow the development of PeproStat.	bermudashorts	Read Full Thread Reply
01/11/2017 10:11	EQUITY DEVELOPMENT EQUITY DEVELOPMENT CHAMPIONING GROWTH COMPANIES Ergomed : Positive PeproStat Data Symbol ERGO Listing AIM Share Price 210p Market Cap £89.6m Sector Healthcare Published 01/11/17 Analyst Elizabeth Klein Recently announced results from the phase II clinical trial of PeproStat were positive. As a result, the probability of PeproStat reaching the market increased from around a third to around two-thirds. This adds £12.7m to the valuation of this programme. As expected the shares saw strong performance on the back of the positive data. There remains significant upside to the bottom end of our 276p-401p valuation. Ergomed acquired Haemostatix in May 2016 for £28m (an initial £8.0m upfront, with the remainder in success-based milestone payments). Haemostatix had developed a new approach to controlling bleeding using a peptide that binds to fibrinogen, targeting a surgical market valued at c. US$2.5bn, growing at c. 6.2% pa. The phase II trial consisted of 169 patients treated (162 evaluable) at 16 sites in five European countries. PeproStat was shown to be clinically and significantly superior to standard of care across three surgery types. The mean time to Haemostasis was reduced by 1.55 minutes for PeproStat vs. standard of care, and favourable by investigator opinion (80.9% surgeons rated PeproStat (blinded) as good to excellent in controlling bleeding vs 59.6% for standard of care). The first commercial deal for a Haemsotatix product was signed late September with a South Korean company, Boryung Pharmaceutical Co. Ergomed will receive an upfront payment and a series of milestone payments as well as a double-digit share of all future product sales in this territory. Further PeproStat deals, along with the start of the next trial in H2 2018 and initial ReadyFlow data, should feature in the news flow over the next 12-18 months, along with further acquisitions to boost the profitability of the Services business. The bottom of the 276p - 401p per share valuation is based on the more conservative “Services-only” sales forecast, discounting completely the potential upside from Development projects. The top of the range adds in these projects with the Haeomstatix programme now making up 60% of the Development valuation.	douglas fir	Read Full Thread Reply
24/10/2017 20:17	hxxps://youtu.be/FFCT_F8zDpQ	mfhmfh	Read Full Thread Reply

Chat Pages: 10 9 8 7 6 5 4 3 2 1

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.